Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 34

1.

Selective depletion strategies in allogeneic stem cell transplantation.

Mielke S, Solomon SR, Barrett AJ.

Cytotherapy. 2005;7(2):109-15. Review.

PMID:
16040390
2.

Functional assessment and specific depletion of alloreactive human T cells using flow cytometry.

Martins SL, St John LS, Champlin RE, Wieder ED, McMannis J, Molldrem JJ, Komanduri KV.

Blood. 2004 Dec 1;104(12):3429-36. Epub 2004 Jul 29.

5.

Ex vivo depletion of alloreactive cells based on CFSE dye dilution, activation antigen selection, and dendritic cell stimulation.

Godfrey WR, Krampf MR, Taylor PA, Blazar BR.

Blood. 2004 Feb 1;103(3):1158-65. Epub 2003 Oct 2.

6.

Definitive separation of graft-versus-leukemia- and graft-versus-host-specific CD4+ T cells by virtue of their receptor beta loci sequences.

Michalek J, Collins RH, Durrani HP, Vaclavkova P, Ruff LE, Douek DC, Vitetta ES.

Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):1180-4. Epub 2003 Jan 16.

7.

Optimized clinical-scale culture conditions for ex vivo selective depletion of host-reactive donor lymphocytes: a strategy for GvHD prophylaxis in allogeneic PBSC transplantation.

Solomon SR, Tran T, Carter CS, Donnelly S, Hensel N, Schindler J, Bahceci E, Ghetie V, Michálek J, Mavroudis D, Read EJ, Vitetta ES, Barrett AJ.

Cytotherapy. 2002;4(5):395-406.

PMID:
12473206
8.

CD25+ immunoregulatory T-cells of donor origin suppress alloreactivity after BMT.

Johnson BD, Konkol MC, Truitt RL.

Biol Blood Marrow Transplant. 2002;8(10):525-35.

9.

CD4(+)CD25(+) immunoregulatory T Cells: new therapeutics for graft-versus-host disease.

Cohen JL, Trenado A, Vasey D, Klatzmann D, Salomon BL.

J Exp Med. 2002 Aug 5;196(3):401-6.

10.

Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: a phase 1/2 study.

André-Schmutz I, Le Deist F, Hacein-Bey-Abina S, Vitetta E, Schindler J, Chedeville G, Vilmer E, Fischer A, Cavazzana-Calvo M.

Lancet. 2002 Jul 13;360(9327):130-7.

PMID:
12126823
11.

P-glycoprotein targeting: a unique strategy to selectively eliminate immunoreactive T cells.

Guimond M, Balassy A, Barrette M, Brochu S, Perreault C, Roy DC.

Blood. 2002 Jul 15;100(2):375-82.

13.
14.

Control of T-cell activation by CD4+ CD25+ suppressor T cells.

Shevach EM, McHugh RS, Piccirillo CA, Thornton AM.

Immunol Rev. 2001 Aug;182:58-67. Review.

PMID:
11722623
16.

Sequential monitoring of chimerism and detection of minimal residual disease after allogeneic blood stem cell transplantation (BSCT) using multiplex PCR amplification of short tandem repeat-markers.

Thiede C, Bornhäuser M, Oelschlägel U, Brendel C, Leo R, Daxberger H, Mohr B, Florek M, Kroschinsky F, Geissler G, Naumann R, Ritter M, Prange-Krex G, Lion T, Neubauer A, Ehninger G.

Leukemia. 2001 Feb;15(2):293-302.

PMID:
11236950
17.

Efficient depletion of alloreactive donor T lymphocytes based on expression of two activation-induced antigens (CD25 and CD69).

Fehse B, Frerk O, Goldmann M, Bulduk M, Zander AR.

Br J Haematol. 2000 Jun;109(3):644-51.

PMID:
10886218
18.

Selective depletion of major and minor histocompatibility antigen reactive T cells: towards prevention of acute graft-versus-host disease.

van Dijk AM, Kessler FL, Stadhouders-Keet SA, Verdonck LF, de Gast GC, Otten HG.

Br J Haematol. 1999 Oct;107(1):169-75.

PMID:
10520038
19.
20.

Depletion of alloreactive T cells by a specific anti-interleukin-2 receptor p55 chain immunotoxin does not impair in vitro antileukemia and antiviral activity.

Montagna D, Yvon E, Calcaterra V, Comoli P, Locatelli F, Maccario R, Fisher A, Cavazzana-Calvo M.

Blood. 1999 May 15;93(10):3550-7.

Supplemental Content

Support Center